...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Usefulness of Xuefu Zhuyu Tang for Patients with Angina Pectoris: A Meta-Analysis and Systematic Review
【24h】

The Usefulness of Xuefu Zhuyu Tang for Patients with Angina Pectoris: A Meta-Analysis and Systematic Review

机译:心绞痛患者Xuefu Zhuyu Tang的有用性:META分析和系统评论

获取原文
获取原文并翻译 | 示例

摘要

Objective. To evaluate the efficacy of Xuefu Zhuyu Tang (XFZYT) for treating angina pectoris (AP). Methods. Six databases were searched (up to December, 2013). Eligible randomized controlled trials (RCTs) evaluating the efficiency of XFZYT plus traditional antianginal medications (TAMs) compared with TAMs alone in patients with AP were included. The outcomes were relief of anginal symptoms (RAS) and improvement of electrocardiogram (ECG) and blood high-density lipoprotein cholesterol (HDL-C) level. Result. Finally 14 RCTs were included. There were evidences that XFZYT combined with TAMs was more effective in improving RAS (RR = 1.29; 95% CI = [1.20,1.38]), ECG (RR = 1.37; 95% CI = [1.22,1.54]), and blood HDL-C level (MD = 0.29 mmol/L; 95% CI = [0.23, 0.35]) compared with TAMs alone. Our meta-analysis also showed the pooled number needed to treat (NNT) of the group with stable angina pectoris (SAP) was smaller in improving RAS (4.2 versus 5.7) and ECG (3.1 versus 5.5) compared with the group with both SAP and unstable angina pectoris (UAP). Conclusion. Combination therapy with XFZYT and TAMs is more effective in treating AP compared with TAMs alone. And XFZYT maybe a more suitable choice for the treatment of SAP. However, the findings should be interpreted with caution due to the mediocre methodological quality of the included RCTs.
机译:客观的。评价Xuefu Zhuyu Tang(Xfzyt)治疗心绞痛(AP)的疗效。方法。搜查了六个数据库(最长到2013年12月)。符合条件的随机对照试验(RCT)与含有AP患者的患者相比,评估XFZYT加上传统抗亚基地药物(TAMS)的效率。结果是缓解角度症状(Ras)和心电图(ECG)和血液高密度脂蛋白胆固醇(HDL-C)水平的改善。结果。最后包括14个RCT。有证据表明,XFZYT与TAMS相结合在改善RAS(RR = 1.29; 95%CI = [1.20,1.38]),ECG(RR = 1.37; 95%CI = [1.22,1.54])和血液HDL -C级(MD = 0.29 mmol / L; 95%CI = [0.23,0.35])与单独的TAMS相比。我们的META分析还显示了用稳定的心绞痛(SAP)治疗(SAP)的群体(NNT)所需的汇总数量在改善RAS(4.2与5.7)和ECG(3.1与5.5)方面较小,与含有SAP和SAP的组不稳定的心绞痛(UAP)。结论。与单独的TAMS相比,XFZYT和TAMS的组合治疗更有效地治疗AP。和Xfzyt可能是SAP治疗更适合的选择。然而,由于包括的RCT的平庸方法质量,应当谨慎地解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号